Email Print Share
December 8, 2016

Silk Proteins for More Stable Vaccines

Almost all vaccines on the market require refrigeration to remain viable – including during transport. Continuous cooling is expensive and especially challenging in developing countries.

To solve this problem, Vaxess Technologies Inc., a small business funded by the National Science Foundation (NSF), has developed a technology that uses silk proteins to create more stable biological platform that keeps vaccines from degrading when exposed to higher temperatures.

Vaxess co-founder Livio Valenti explains that the silk proteins are particularly resilient to temperature changes and help control moisture content.

Vaxess is supported through the NSF Small Business Innovation Research/Small Business Technology Transfer (SBIR/STTR) program, a $188 million activity that catalyzes commercialization of high-risk technological innovations via research and development grants to small businesses and startups. Vaxess was one of 50 NSF-funded startups and small businesses with innovative biotech, based on fundamental research, on display at the 2016 BIO International Convention.

More at NSF.gov/SBIR.

Original air date: December 8, 2016.

Credit: NSF


Images and other media in the National Science Foundation Multimedia Gallery are available for use in print and electronic material by NSF employees, members of the media, university staff, teachers and the general public. All media in the gallery are intended for personal, educational and nonprofit/non-commercial use only.

Videos credited to the National Science Foundation, an agency of the U.S. Government, may be distributed freely. However, some materials within the videos may be copyrighted. If you would like to use portions of NSF-produced programs in another product, please contact the Video Team in the Office of Legislative and Public Affairs at the National Science Foundation.

Additional information about general usage can be found in Conditions.